Skip to main content
. 2021 Nov 24;19:387. doi: 10.1186/s12951-021-01131-9

Fig. 6.

Fig. 6

The application of MPDA@SPIO/SA-PEI/AFP-Fth nanocomplexes as an effective MR contrast agent in the early stage of HCC.

Reprinted (adapted) with permission from Fan et al. [121]. (Copyright © 2021Fan et al. Journal of Nanobiotechnology published by BioMed Central). http://creativecommons.org/licenses/by/4.0/